Skip to main content

Research Highlights

Aug 09, 2022

Publication Overview

The Division of Cardiothoracic Surgery has 62 publications in 2022 as of July. 

Adult Cardiac 31
Pediatric 10
Thoracic 15
Translational 6
researchers in the CVRTI lab
CVRTI Aromolaran Lab - Dr. Aromolaran, Kelly and Andrea - Cardiomyocyte Electophysiology

Sample of publications:

Adult Cardiac

  • Nakashima T, Ogata S, Noguchi T, Nishimura K, Hsu CH, Sefa N, Haas NL, Bĕlohlávek J, Pellegrino V, Tonna JE, Haft J, Neumar RW.Resuscitation. 2022 Jul 3;177:43-51. doi: 10.1016/j.resuscitation.2022.06.022. Online ahead of print.PMID: 35788020
  • Sadeh B, Ugolini S, Pinzon OW, Potapov EV, Selzman CH, Bader F, Zuckermann AO, Gomez-Mesa JE, Shah KS, Alharethi R, Morejon-Barragan P, Hanff T, Goldraich LA, Farrero M, MacDonald PS, Drakos S, Mehra MR, Stehlik J.Clin Transplant. 2022 Jul;36(7):e14733. doi: 10.1111/ctr.14733. Epub 2022 Jun 8.PMID: 35652422
  • Owyang CG, Donnat C, Brodie D, Gershengorn HB, Hua M, Qadir N, Tonna JE.Artif Organs. 2022 Jul;46(7):1369-1381. doi: 10.1111/aor.14193. Epub 2022 Feb 11.PMID: 35122290
  • Pereira SJ.J Card Surg. 2022 Jun;37(6):1671-1673. doi: 10.1111/jocs.16399. Epub 2022 Mar 14.PMID: 35288984


  • Robertson DM, Boucek DM, Martin MH, Gray RG, Griffiths ER, Eckhauser AW, Ou Z, Lambert LM, Williams RV, Husain SA.Am J Cardiol. 2022 Jun 9:S0002-9149(22)00532-X. doi: 10.1016/j.amjcard.2022.04.056. Online ahead of print.PMID: 35691707
  • Eckhauser AW.J Am Coll Cardiol. 2022 Mar 29;79(12):1181-1182. doi: 10.1016/j.jacc.2022.01.024.PMID: 35331413
  • Hobbs RD, Eckhauser AW.J Thorac Cardiovasc Surg. 2022 Feb 19:S0022-5223(22)00208-2. doi: 10.1016/j.jtcvs.2022.02.023. Online ahead of print.PMID: 35260281


  • Mitzman B.Semin Thorac Cardiovasc Surg. 2022 Jun 30:S1043-0679(22)00148-4. doi: 10.1053/j.semtcvs.2022.06.016. Online ahead of print.PMID: 35781041 No abstract available.
  • Mitzman B, Wang X, Haaland B, Varghese TK Jr.J Surg Oncol. 2022 May 23. doi: 10.1002/jso.26923. Online ahead of print.PMID: 35603987
  • Elfaki LA, Luc JGY, Antonoff MB, Cooke DT, Arora RC, Stamp N, Varghese TK Jr, Ouzounian M.JTCVS Open. 2022 May 13. doi: 10.1016/j.xjon.2022.05.005. Online ahead of print.PMID: 35664693
  • Brajcich BC, Stigall K, Walsh DS, Varghese TK, Barber AE, Kralovich KA, Wescott AB, Pockaj BA, Ko CY, Laronga C.J Am Coll Surg. 2022 Mar 1;234(3):384-394. doi: 10.1097/XCS.0000000000000055.PMID: 35213503

Translational Science

  • Ishidoya Y, Kwan E, Dosdall DJ, Macleod RS, Navaravong L, Steinberg BA, Jared Bunch T, Ranjan R.J Cardiovasc Electrophysiol. 2022 Jul;33(7):1460-1471. doi: 10.1111/jce.15554. Epub 2022 Jun 3.PMID: 35644036
  • Ishidoya Y, Kwan E, Dosdall DJ, Macleod RS, Navaravong L, Steinberg BA, Bunch TJ, Ranjan R.J Cardiovasc Electrophysiol. 2022 Jul;33(7):1450-1459. doi: 10.1111/jce.15553. Epub 2022 Jun 7.PMID: 35606341
  • Javan H, Li L, Schaaf CL, Lee YS, Salama ME, Dinarello CA, Selzman CH.Ann Thorac Surg. 2022 Jul;114(1):98-107. doi: 10.1016/j.athoracsur.2021.07.044. Epub 2021 Aug 19.PMID: 34419440
  • Shah AR, Khan MS, Lange M, Hirahara AM, Stoddard G, Ranjan R, Dosdall DJ.Cardiovasc Eng Technol. 2022 Jun;13(3):452-465. doi: 10.1007/s13239-021-00593-0. Epub 2021 Nov 23.PMID: 34816378

A full list of our research publications from the past couple of years can be found here.

Submitted Funding

Adult Cardio

  • Craig Selzman, MD
    • Title: Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)
    • Sponsor: BioCardia, Inc
  • Joseph Tonna, MD
    • Title: ECMO Trial- R01
    • Sponsor: DHHS National Institutes of Health
  • Jason Glotzbach, MD
    • Title: K08 Resub 
    • Sponsor: DHHS National Institutes of Health

Translational Science

  • Aromolara Ademuyiwa, PhD
    • Title(s): R01 PA 20-185 Targeting IL-6; Role for Leukorienes
    • Sponsor: DHHS National Institutes of Health 
CVRTI researcher looks through microscope
Photo Credit: CVRTI LAB

Study Highlight

PI: Craig Selzman, MD 

  • Project: A prospective, randomized, active (warfarin) controlled, parallel-arm clinical trial to determine if patients with an On-X aortic valve can be maintained safely and effectively on the factor Xa inhibitor apixaban. 
  • Background: There is an unmet clinical need for an alternative to warfarin, such as a direct oral anticoagulant (DOAC), as anticoagulation in patients with an aortic mechanical prosthetic valve. The primary objective is to determine if apixaban is superior to warfarin (INR 2.0-3.0) for patients with an On-X mechanical heart valve for the primary outcome of valve thrombosis and valve-related thromboembolism. 
  • Study Design: Participants are eligible if they are at least 18 years of age, at least 3 months out from an On-X aortic valve implantation, and currently managing their anticoagulation with warfarin. If enrolled, they will be followed for 2 years. Participants will be randomized to either continue warfarin or switch to apixaban.

Participants randomized to apixaban will receive 5 mg twice daily (BID), or apixaban 2.5 mg BID in participants with 2 or 3 of the following characteristics:
•    age ≥ 80 years
•    weight ≤ 60 kilograms
•    creatinine ≥ 1.5 mg/dL (133 micromol/L)

For participants randomized to apixaban, INR testing will be performed on the current warfarin dose with the following algorithm to initiate apixaban:
1. INR < 2; stop warfarin and start apixaban
2. INR 2.0 to 3.0; hold warfarin for 2 days, start apixaban on day 3
3. INR > 3.0 to 4.0; hold warfarin for 4 days, start apixaban on day 5
4. INR > 4.0; hold warfarin for 2 days, recheck INR, refer to steps 1, 2, or 3

For more information: 

Don’t see your publication or research highlight? Want to share new updates or projects in the works?

Please contact Margaret Carlson

Email Margaret